Close Alert Banner
Skip to Content
Visit BORNOntario.caVisit BORN.ca
COVID-19: Information for PregnancyContact Us
FR

BORN Ontario Logo

Contact Us icon
  • What is Prenatal Screening?
    • What Do We Screen For?
    • Multiple Marker Screening (MMS)
    • Non-Invasive Prenatal Testing
    • Nuchal Translucency Ultrasound
    • Options by Pregnancy Stage
    • For Twins or More Than Two Babies
    • Nominate a Condition
  • Results and Next Steps
    • Multiple Marker Screening (MMS) Results
    • Non-invasive Prenatal Testing (NIPT) Results
    • Diagnostic Testing
  • Requisitions and Provider Tools
    • Multiple Marker Screening (MMS) Requisitions
    • Non-invasive Prenatal Testing (NIPT) Requisitions
    • Provider Tools
  • For Sonographers
    • NT Registration
    • Log in to the BIS
    • NT Quality Assurance
    • Resources and Point of Care Tools
    • Facilities that offer Nuchal Translucency ultrasound
  • About Us
    • Contact Us
    • Careers
    • Events Calendar
    • Get Involved
    • PSO News
    • Subscribe to PSO updates
HomeRequisitions and Provider ToolsMultiple Marker Screening (MMS) Requisitions
  • Open new window to share this page via Facebook Facebook
  • Open new window to share this page via LinkedIn LinkedIn
  • Open new window to share this page via Twitter Twitter
  • Email this page Email

Multiple Marker Screening (MMS) Requisitions

Multiple Marker Screening (MMS) - most commonly enhanced First Trimester Screening (eFTS) and Second Trimester  Screening (STS) - can be performed for all singleton pregnancies. These tests are done by three provincial laboratories. Check out our interactive map to learn which of the three requisitions you should use. 

Maternal Serum AFP is a screen for Open Neural Tube Defects and should only be ordered when geographical location or clinical factors limit high-quality anatomy ultrasound screening. This test does not screen for trisomy 21 or trisomy 18. 

NYGH req
North York General Hospital Requisition
req trillium
Trillium Health Partners – Credit Valley Hospital Requisition
MSH requisition
Mount Sinai Hospital Requisition

Requisition Updates

Take note that a new requisition form (version 3, May 2022) is now in use and the following changes were implemented:

The requisition has been renamed “Multiple Marker Screening (MMS) Requisition”.

This change occurred to describe the specific type of prenatal screening that can be ordered using this requisition. 

Maternal Serum Screening (MSS) has been renamed, “Second Trimester Screening” or STS.

This change applies to the name only, to improve understanding of when in pregnancy this screening can be done; the timing and analytes for this screen remain unchanged. 

The option of ordering First Trimester Screening (FTS) for twin pregnancies has been removed.

This change occurred to reflect that First Trimester Screening (FTS) for twin pregnancies has been discontinued in Ontario. OHIP-funded Non-Invasive Prenatal Testing (NIPT) is available for all viable twin pregnancies. NIPT can be ordered using the OHIP-funded NIPT requisition with the MOH Eligibility Criteria Form. 

If NIPT is done, a stand-alone nuchal translucency ultrasound should always still be offered to all pregnancies, where available, due to the additional benefits that this ultrasound offers.  The ultrasound can be ordered using a requisition for a facility providing NT ultrasounds. 

A new test menu option has been added: "NT + Second Trimester Screening (NT + STS) (suspected or confirmed vanishing twin/co-twin demise only)".

This change was made to improve the screening process for pregnancies with a suspected or confirmed vanishing twin/co-twin demise. 

Select this menu option if there is a suspected or confirmed vanishing twin/co-twin demise known at the time of completing the MMS Requisition. NT + STS includes an NT ultrasound (11w2d – 13w3d) and second trimester blood sample (14w0d - 20w6d);

The blood draw cannot be done until 8 weeks after demise. You can calculate the date after which the pregnant individual can have their blood drawn and record this on the requisition within the NT + STS section, where indicated. For example, if the demise was estimated to have occurred at 10w0d, the pregnant individual could have the  blood draw after 18w0d (and up to a maximum of 20w6d).

ultrasound probe
For Ultrasound Practitioners - How to Complete Requisition

How Do I Order Multiple Marker Screening?

Step-by-step Instructions for ordering each screening modality can be found below:

icon of ultrasound and test tube
Order eFTS

For singleton pregnancies between 11 weeks 2 days to 13 weeks 3 days gestation

Learn More
icon of test tube
Order STS

For singleton pregnancies between 14 weeks and 20 weeks 6 days gestation

Learn More
calendar icon
Order NT + STS

For singleton pregnancies with a history of vanishing twin / co-twin demise

Learn More

Which Multiple Marker Screen Should I Offer?

The Multiple Marker Screening options that are possible for a pregnant individual in your care depend on gestational age, availability of nuchal translucency (NT) ultrasound, and whether there is a history of a vanishing twin / co-twin demise. Please select the statement that applies to the pregnant individual in your care to learn which options apply for them.

Pregnant individual is in the first trimester of pregnancy

The optimal Multiple Marker Screening modality for most singleton pregnancies is enhanced First Trimester Screening (done between 11 weeks 2 days to 13 weeks 3 days gestation).  

Special scenarios:

  • If the nuchal translucency (NT) ultrasound is not available, offer Second Trimester Screening instead of enhanced First Trimester Screening. 
  • If a vanishing twin / co-twin demise is identified prior to initiating prenatal screening, enhanced First Trimester Screening cannot be done. Instead, offer "NT + Second Trimester Screening". This includes nuchal translucency (NT) ultrasound (between 11 weeks 2 days to 13 weeks 3 days gestation), followed by a second trimester blood sample (done between 14 weeks 0 days to 20 weeks 6 days gestation).

Multiple Marker Screening is not recommended when a NIPT result is pending or NIPT results were conclusively reported as "high risk" or "low risk".  Individuals who have inconclusive NIPT result(s) can have Multiple Marker Screening as an alternative test.  

Pregnant individual is in the second trimester of pregnancy

The Multiple Marker Screening modality available for singleton pregnancies in the second trimester is "Second Trimester Screening" (done between 14 weeks 0 days to 20 weeks 6 days gestation). Second Trimester Screening is also possible for confirmed or suspected vanishing twin/co-twin demise scenarios. 

Multiple Marker Screening is not recommended when a NIPT result is pending or NIPT results were conclusively reported as "high risk" or "low risk".  Individuals who have inconclusive NIPT result(s) can have Multiple Marker Screening as an alternative test.  

Pregnant individual is in the third trimester of pregnancy

There are no Multiple Marker Screening modalities available for singleton pregnancies in the the third trimester. The prenatal screening option at this stage in the pregnancy is Non-Invasive Prenatal Testing (OHIP-funded or private-pay).

Every pregnant individual in your care should be provided with the option of Non-Invasive Prenatal Testing (OHIP-funded or private-pay, depending on the scenario), as an alternative screen to Multiple Marker Screening. 

People have the option of declining any type of prenatal screening for trisomy 21 and trisomy 18. These individuals can still choose to have a stand-alone 11-14 week ultrasound (including nuchal translucency measurement where available), and a 18-22 week ultrasound.

  • Requisitions and Provider Tools
    • Multiple Marker Screening (MMS) Requisitions
    • Non-invasive Prenatal Testing (NIPT) Requisitions
    • Provider Tools

Contact Us

Subscribe to this page

Prenatal Screening Ontario logo

BORN Ontario logo

Our Website

  • What is Prenatal Screening?
  • Results and Next Steps
  • Requisitions and Provider Tools
  • For Sonographers
  • About Us

Helpful Links

  • Contact Us
  • Sitemap
  • Website Feedback
  • View our Facebook Page
  • View our Twitter Page

Contact Us

Prenatal Screening Ontario 
CHEO Research Institute 
Centre for Practice-Changing Research Building 
401 Smyth Road 
Ottawa, ON K1H 8L1

Phone: 613-737-2281

Toll-Free: 1-833-351-6490

Monday to Friday, 9:00 AM to 3:00 PM

Copyright © 2022 BORN Ontario | Funded by the Government of Ontario

Designed by eSolutionsGroup

Close Old Browser Notification
Browser Compatibility Notification
It appears you are trying to access this site using an outdated browser. As a result, parts of the site may not function properly for you. We recommend updating your browser to its most recent version at your earliest convenience.